Oncology Pharmaceuticals Market By Indication (Blood Cancer, Breast Cancer, Prostate Cancer, Basal Cell Cancer, Skin Cancer, Colorectal Cancer, Lung Cancer, Renal Cancer, Bladder Cancer, Lymphoma, and Others); By Route of Administration (Oral, Intravenous, Subcutaneous, Intrathecal, Intraventricular, and Others); By Application (Drug Therapies (Antimetabolites, Antitumor Antibiotics, Asparagine-Specific Enzymes, Bisphosphonates & Biosimilars, DNA Damaging Agents & Alkylating Agents, Inhibitors, Monoclonal Antibodies & Others), Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy, Stem Cell Transplant, and Others); By Dosage (mg) (50 to 100, 200, 500, and Others); By Region (U.S., Canada, Mexico, Rest of North America, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America); – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 - 2029
Industry Trends
According to multiple surveys, the number of people suffering from different types of cancer has been increasing. In 2020, nearly 537,000 people were diagnosed with lymphoma. Many people affected by different types of blood cancers need new treatment options. Hence, the growing incidence of blood cancer is contributing towards the growth of global oncology pharmaceuticals market. Many factors are driving the global oncology pharmaceuticals market but the most important factor is the growing awareness pertaining to early diagnosis of cancer. Most forms of cancers are curable only if treatment starts at an early stage. Due to technological advancements and discovery of new methods of diagnosis in the global oncology pharmaceuticals market, early diagnosis is possible for cancer, which is facilitating early treatment. The major factor restraining the growth of global oncology pharmaceuticals market growth is a series of concerns regarding side effects of cancer drugs. Moreover, concerns pertaining to high cost of treatments is also impacting the revenue generation in the global market.
The invention of new medical devices that can reduce the time required for diagnosis procedure along with discovery of devices that can speed up the medical treatment is estimated to influence the growth of global oncology pharmaceuticals market over the forecast period. Researchers in the USA have discovered an experimental cancer drug called AR-12. This drug inhibits the COVID-19 virus from infecting cells and replicating. To a large extent, this drug can help to cure coronavirus. AR-12 inhibits proteins called cellular chaperones. These proteins are required to maintain the right three-dimensional (3D) shape of viral proteins. The shape of coronavirus is critical to its ability to infect a patient and replicate itself in the patient's body. GRP78, one of the cellular chaperones inhibited by AR-12, is essential for the reproduction of all viruses. Acting as a sort of cellular stress sensor, GRP78 is required for the life cycle of all mammalian viruses. Hence, the adoption of AR-12 has been declared to be safe regarding COVID-19 treatment.
Absolute Market Insights reports, the global oncology pharmaceuticals market is likely to grow at 11.9% CAGR during the 2021-2029 period, and reach a valuation of US$ 439.87 Bn by 2029.
Oncology Pharmaceuticals Market Revenue & Forecast, (US$ Million), 2015 – 2029
Indication Outlook:
By indication, this research report from Absolute Markets Insights about global oncology pharmaceuticals market covers blood cancer, breast cancer, prostate cancer, basal cell cancer, skin cancer, colorectal cancer, lung cancer, renal cancer, bladder cancer, lymphoma, and others. In 2020, the blood cancer segment held the largest market share. During the forecast period, breast cancer segment is estimated to register highest growth rate. The survival rate through the advancement in treatment modalities for breast cancer has increased substantially. Moreover, according to the data published by International Agency for Research on Cancer (IARC) in December 2020, breast cancer is now among the most commonly-diagnosed form of Cancer. The Cancer communities globally along with World Health Organization (WHO) are undertaking initiatives to address the growing concern pertaining to breast cancer
Application Outlook:
The application segment in the global oncology pharmaceuticals market is broadly segmented into drug therapies, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplant, and others. The drug therapies category has been further calssified into antimetabolites, antitumor antibiotics, asparagine-specific enzymes, bisphosphonates & biosimilars, DNA damaging agents & alkylating agents, inhibitors, monoclonal antibodies, and others. In 2020, targeted therapy category held the largest market share.
During the forecast period, immunotherapy segment is anticipated to register highest growth rate. Immunotherapy is defined as a type of cancer treatment that helps patient's immune system to fight cancer. As the immune system helps the body to fight infections and other diseases, it is made up of white blood cells and organs as well as tissues of the lymph system. Being a biological therapy, immunotherapy uses substances made from living organisms to treat cancer. The immune system can detect as well as destroy abnormal cells. It can also prevent or curb the growth of many cancers. Tumor-infiltrating lymphocytes (TILs) are immune cells that are often found in and around tumors. TILs are a sign of immune system responding to the tumor.
Route of Administration Outlook:
This market report segments the route of administration segment in the global oncology pharmaceuticals market into oral, intravenous, subcutaneous, intrathecal, intraventricular, and others. In 2020, the intravenous administration category held the largest market share.
During the forecast period, intrathecal administration category is estimated to make progress and witness highest growth rate. Intrathecal drug delivery has been observed as an effective option regarding pain management for those patients who are suffering from chronic pain and cancer pain. Anticancer drugs are injected into the fluid-filled space between the thin layers of that tissue, which covers the human brain and spinal cord. The delivery of drugs into the intrathecal space not only provides superior analgesia, but the smaller doses of analgesics minimizes the possible side effects of drug. Delivering the medication directly into the cerebrospinal fluid (CSF) reduces the systemic side effects of drugs. The direct delivery to the site of action also ensures a more rapid as well as effective response.
Dosage Outlook:
Based on dosage, the global oncology pharmaceuticals market is segmented into 50 to 100 milligrams (mg), 200 mg, 500 mg, and others. The potency of every drug is different as some drugs are mild while others are strong. Hence, for treatment, the decision to give a strong dose or mild dose of any drug is always at the discretion of doctor, depending on the medical condition of patient and the nature of ailment.
Regional Outlook:
In 2020, North America accounted for the largest share in the global oncology pharmaceuticals market. During the forecast period, Asia Pacific region is estimated to withstand fastest growth rate due to increasing awareness about cancer owing to which more people seeking cancer treatment, along with high density of population in countries like China and India suffering from various forms of cancer. Rising per capita income in fast growing economies like India, South Korea, and China is making treatment for some types of cancer, affordable to people. Some of the key market players in this market are also located in Asian countries like India, Japan, South Korea, and Singapore. Other factors contributing to the market growth include increasing healthcare expenditure and increasing budgetary allocation towards healthcare infrastructure by governments in Asian countries.
Competitive Landscape Outlook:
The companies operating in the global oncology pharmaceuticals market are constantly investing towards development of effective treatment options catering to various areas of cancers, which also marks a significant growth opportunity for the global market over the forecast period. The market participants such as Pfizer Inc., Sanofi and Johnson & Johnson Services Inc. amongst others are undertaking substantial investments in various fields of Cancer. Some of the major players operating in the global oncology pharmaceuticals market are Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited, amongst others.
Global Oncology Pharmaceuticals Market:
- By Indication
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Basal Cell Cancer
- Skin Cancer
- Colorectal Cancer
- Lung Cancer
- Renal Cancer
- Bladder Cancer
- Lymphoma
- Others
- By Application
- Drug Therapies
- Antimetabolites
- Antitumor Antibiotics
- Asparagine-Specific Enzymes
- Bisphosphonates and Biosimilars
- DNA Damaging Agents and Alkylating Agents
- Inhibitors
- Monoclonal Antibodies
- Others
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormone Therapy
- Stem Cell Transplant
- Others
- By Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Intrathecal
- Intraventricular
- Others
- By Dosage (mg)
- 50 to 100
- 200
- 500
- Others
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1.
Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key Target Audiences
3.
Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations and Insights from AMI’s Perspective**
5.
Holistic Overview of Oncology Pharmaceuticals Market
6.
Market Synopsis:
Oncology Pharmaceuticals Market
7.
Oncology Pharmaceuticals Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Oncology Pharmaceuticals Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Oncology
Pharmaceuticals Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Oncology Pharmaceuticals Market
8.
Global Oncology Pharmaceuticals Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Oncology Pharmaceuticals Market Revenue (US$ Mn)
8.2. Global Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
8.2.1. Blood Cancer
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Breast Cancer
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Prostate Cancer
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Basal Cell Cancer
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Skin Cancer
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.2.6. Colorectal Cancer
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2020
8.2.6.3. Market Forecast, 2021 - 2029
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 - 2020
8.2.6.5.1.2. Market Forecast, 2021 - 2029
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2020
8.2.6.5.2.2. Market Forecast, 2021 - 2029
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2020
8.2.6.5.3.2. Market Forecast, 2021 - 2029
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2020
8.2.6.5.4.2. Market Forecast, 2021 - 2029
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 - 2020
8.2.6.5.5.2. Market Forecast, 2021 - 2029
8.2.7. Lung Cancer
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 - 2020
8.2.7.3. Market Forecast, 2021 - 2029
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market Estimation, 2015 - 2020
8.2.7.5.1.2. Market Forecast, 2021 - 2029
8.2.7.5.2. Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2020
8.2.7.5.2.2. Market Forecast, 2021 - 2029
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2020
8.2.7.5.3.2. Market Forecast, 2021 - 2029
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2020
8.2.7.5.4.2. Market Forecast, 2021 - 2029
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market Estimation, 2015 - 2020
8.2.7.5.5.2. Market Forecast, 2021 - 2029
8.2.8. Renal Cancer
8.2.8.1. Definition
8.2.8.2. Market Estimation and Penetration, 2015 - 2020
8.2.8.3. Market Forecast, 2021 - 2029
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.2.8.5. Regional Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market Estimation, 2015 - 2020
8.2.8.5.1.2. Market Forecast, 2021 - 2029
8.2.8.5.2. Europe
8.2.8.5.2.1. Market Estimation, 2015 - 2020
8.2.8.5.2.2. Market Forecast, 2021 - 2029
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market Estimation, 2015 - 2020
8.2.8.5.3.2. Market Forecast, 2021 - 2029
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market Estimation, 2015 - 2020
8.2.8.5.4.2. Market Forecast, 2021 - 2029
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market Estimation, 2015 - 2020
8.2.8.5.5.2. Market Forecast, 2021 - 2029
8.2.9. Bladder Cancer
8.2.9.1. Definition
8.2.9.2. Market Estimation and Penetration, 2015 - 2020
8.2.9.3. Market Forecast, 2021 - 2029
8.2.9.4. Compound Annual Growth Rate (CAGR)
8.2.9.5. Regional Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market Estimation, 2015 - 2020
8.2.9.5.1.2. Market Forecast, 2021 - 2029
8.2.9.5.2. Europe
8.2.9.5.2.1. Market Estimation, 2015 - 2020
8.2.9.5.2.2. Market Forecast, 2021 - 2029
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market Estimation, 2015 - 2020
8.2.9.5.3.2. Market Forecast, 2021 - 2029
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market Estimation, 2015 - 2020
8.2.9.5.4.2. Market Forecast, 2021 - 2029
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market Estimation, 2015 - 2020
8.2.9.5.5.2. Market Forecast, 2021 - 2029
8.2.10. Lymphoma
8.2.10.1. Definition
8.2.10.2. Market Estimation and Penetration, 2015 - 2020
8.2.10.3. Market Forecast, 2021 - 2029
8.2.10.4. Compound Annual Growth Rate (CAGR)
8.2.10.5. Regional Bifurcation
8.2.10.5.1. North America
8.2.10.5.1.1. Market Estimation, 2015 - 2020
8.2.10.5.1.2. Market Forecast, 2021 - 2029
8.2.10.5.2. Europe
8.2.10.5.2.1. Market Estimation, 2015 - 2020
8.2.10.5.2.2. Market Forecast, 2021 - 2029
8.2.10.5.3. Asia Pacific
8.2.10.5.3.1. Market Estimation, 2015 - 2020
8.2.10.5.3.2. Market Forecast, 2021 - 2029
8.2.10.5.4. Middle East and Africa
8.2.10.5.4.1. Market Estimation, 2015 - 2020
8.2.10.5.4.2. Market Forecast, 2021 - 2029
8.2.10.5.5. Latin America
8.2.10.5.5.1. Market Estimation, 2015 - 2020
8.2.10.5.5.2. Market Forecast, 2021 - 2029
8.2.11. Others
8.2.11.1. Definition
8.2.11.2. Market Estimation and Penetration, 2015 - 2020
8.2.11.3. Market Forecast, 2021 - 2029
8.2.11.4. Compound Annual Growth Rate (CAGR)
8.2.11.5. Regional Bifurcation
8.2.11.5.1. North America
8.2.11.5.1.1. Market Estimation, 2015 - 2020
8.2.11.5.1.2. Market Forecast, 2021 - 2029
8.2.11.5.2. Europe
8.2.11.5.2.1. Market Estimation, 2015 - 2020
8.2.11.5.2.2. Market Forecast, 2021 - 2029
8.2.11.5.3. Asia Pacific
8.2.11.5.3.1. Market Estimation, 2015 - 2020
8.2.11.5.3.2. Market Forecast, 2021 - 2029
8.2.11.5.4. Middle East and Africa
8.2.11.5.4.1. Market Estimation, 2015 - 2020
8.2.11.5.4.2. Market Forecast, 2021 - 2029
8.2.11.5.5. Latin America
8.2.11.5.5.1. Market Estimation, 2015 - 2020
8.2.11.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for
Channeling Investments
8.3.1. By Indication
9.
Global Oncology Pharmaceuticals Market Analysis and
Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
9.2.1. Drug Therapies (Definition, Market Estimation and
Penetration, 2015 - 2020, Market Estimation (2015 - 2020), Market Forecast
(2021 - 2029), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Antimetabolites, Antitumor Antibiotics, Asparagine-Specific
Enzymes, Bisphosphonates and Biosimilars, DNA Damaging Agents and Alkylating
Agents, Inhibitors, Monoclonal Antibodies, Others)
9.2.1.1. Antimetabolites
9.2.1.2. Antitumor Antibiotics
9.2.1.3. Asparagine-Specific Enzymes
9.2.1.4. Bisphosphonates and Biosimilars
9.2.1.5. DNA Damaging Agents and Alkylating Agents
9.2.1.6. Inhibitors
9.2.1.7. Monoclonal Antibodies
9.2.1.8. Others
9.2.2. Radiation Therapy
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.2.3. Chemotherapy
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 - 2020
9.2.3.5.1.2. Market Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2020
9.2.3.5.2.2. Market Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2020
9.2.3.5.3.2. Market Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2020
9.2.3.5.4.2. Market Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 - 2020
9.2.3.5.5.2. Market Forecast, 2021 - 2029
9.2.4. Immunotherapy
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2015 - 2020
9.2.4.5.1.2. Market Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2020
9.2.4.5.2.2. Market Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2020
9.2.4.5.3.2. Market Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2020
9.2.4.5.4.2. Market Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2015 - 2020
9.2.4.5.5.2. Market Forecast, 2021 - 2029
9.2.5. Targeted Therapy
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2020
9.2.5.3. Market Forecast, 2021 - 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market Estimation, 2015 - 2020
9.2.5.5.1.2. Market Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2020
9.2.5.5.2.2. Market Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2020
9.2.5.5.3.2. Market Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2020
9.2.5.5.4.2. Market Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market Estimation, 2015 - 2020
9.2.5.5.5.2. Market Forecast, 2021 - 2029
9.2.6. Hormone Therapy
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2020
9.2.6.3. Market Forecast, 2021 - 2029
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market Estimation, 2015 - 2020
9.2.6.5.1.2. Market Forecast, 2021 - 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2020
9.2.6.5.2.2. Market Forecast, 2021 - 2029
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2020
9.2.6.5.3.2. Market Forecast, 2021 - 2029
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2020
9.2.6.5.4.2. Market Forecast, 2021 - 2029
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market Estimation, 2015 - 2020
9.2.6.5.5.2. Market Forecast, 2021 - 2029
9.2.7. Stem Cell Transplant
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2020
9.2.7.3. Market Forecast, 2021 - 2029
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market Estimation, 2015 - 2020
9.2.7.5.1.2. Market Forecast, 2021 - 2029
9.2.7.5.2. Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2020
9.2.7.5.2.2. Market Forecast, 2021 - 2029
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2020
9.2.7.5.3.2. Market Forecast, 2021 - 2029
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2020
9.2.7.5.4.2. Market Forecast, 2021 - 2029
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market Estimation, 2015 - 2020
9.2.7.5.5.2. Market Forecast, 2021 - 2029
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2020
9.2.8.3. Market Forecast, 2021 - 2029
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market Estimation, 2015 - 2020
9.2.8.5.1.2. Market Forecast, 2021 - 2029
9.2.8.5.2. Europe
9.2.8.5.2.1. Market Estimation, 2015 - 2020
9.2.8.5.2.2. Market Forecast, 2021 - 2029
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market Estimation, 2015 - 2020
9.2.8.5.3.2. Market Forecast, 2021 - 2029
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market Estimation, 2015 - 2020
9.2.8.5.4.2. Market Forecast, 2021 - 2029
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market Estimation, 2015 - 2020
9.2.8.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for
Channeling Investments
9.3.1. By Application
10.
Global Oncology Pharmaceuticals Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Intravenous
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Subcutaneous
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.2.4. Intrathecal
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2020
10.2.4.5.1.2. Market Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2020
10.2.4.5.2.2. Market Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2020
10.2.4.5.3.2. Market Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2020
10.2.4.5.4.2. Market Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2020
10.2.4.5.5.2. Market Forecast, 2021 - 2029
10.2.5. Intraventricular
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 - 2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2020
10.2.5.5.1.2. Market Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2020
10.2.5.5.2.2. Market Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2020
10.2.5.5.3.2. Market Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2020
10.2.5.5.4.2. Market Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2020
10.2.5.5.5.2. Market Forecast, 2021 - 2029
10.2.6. Others
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 - 2020
10.2.6.3. Market Forecast, 2021 - 2029
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 - 2020
10.2.6.5.1.2. Market Forecast, 2021 - 2029
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 - 2020
10.2.6.5.2.2. Market Forecast, 2021 - 2029
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 - 2020
10.2.6.5.3.2. Market Forecast, 2021 - 2029
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 - 2020
10.2.6.5.4.2. Market Forecast, 2021 - 2029
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 - 2020
10.2.6.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for
Channeling Investments
10.3.1. By Route of Administration
11.
Global Oncology Pharmaceuticals Market Analysis and
Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
11.2.1. 50 to 100
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2020
11.2.1.5.1.2. Market Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2020
11.2.1.5.2.2. Market Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2020
11.2.1.5.3.2. Market Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2020
11.2.1.5.4.2. Market Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2020
11.2.1.5.5.2. Market Forecast, 2021 - 2029
11.2.2. 200
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2020
11.2.2.5.1.2. Market Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2020
11.2.2.5.2.2. Market Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2020
11.2.2.5.3.2. Market Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2020
11.2.2.5.4.2. Market Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2020
11.2.2.5.5.2. Market Forecast, 2021 - 2029
11.2.3. 500
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market Estimation, 2015 - 2020
11.2.3.5.1.2. Market Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2020
11.2.3.5.2.2. Market Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2020
11.2.3.5.3.2. Market Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2020
11.2.3.5.4.2. Market Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2020
11.2.3.5.5.2. Market Forecast, 2021 - 2029
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Estimation and Penetration, 2015 - 2020
11.2.4.3. Market Forecast, 2021 - 2029
11.2.4.4. Compound Annual Growth Rate (CAGR)
11.2.4.5. Regional Bifurcation
11.2.4.5.1. North America
11.2.4.5.1.1. Market Estimation, 2015 - 2020
11.2.4.5.1.2. Market Forecast, 2021 - 2029
11.2.4.5.2. Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2020
11.2.4.5.2.2. Market Forecast, 2021 - 2029
11.2.4.5.3. Asia Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2020
11.2.4.5.3.2. Market Forecast, 2021 - 2029
11.2.4.5.4. Middle East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2020
11.2.4.5.4.2. Market Forecast, 2021 - 2029
11.2.4.5.5. Latin America
11.2.4.5.5.1. Market Estimation, 2015 - 2020
11.2.4.5.5.2. Market Forecast, 2021 - 2029
11.3. Key Segment for
Channeling Investments
11.3.1. By Dosage (mg)
12.
North America Oncology Pharmaceuticals Market Analysis
and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Oncology Pharmaceuticals Market Revenue
(US$ Mn)
12.2. North America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Indication
12.2.1. Blood Cancer
12.2.2. Breast Cancer
12.2.3. Prostate Cancer
12.2.4. Basal Cell Cancer
12.2.5. Skin Cancer
12.2.6. Colorectal Cancer
12.2.7. Lung Cancer
12.2.8. Renal Cancer
12.2.9. Bladder Cancer
12.2.10. Lymphoma
12.2.11. Others
12.3. North America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Application
12.3.1. Drug Therapies
12.3.1.1. Antimetabolites
12.3.1.2. Antitumor Antibiotics
12.3.1.3. Asparagine-Specific Enzymes
12.3.1.4. Bisphosphonates and Biosimilars
12.3.1.5. DNA Damaging Agents and Alkylating Agents
12.3.1.6. Inhibitors
12.3.1.7. Monoclonal Antibodies
12.3.1.8. Others
12.3.2. Radiation Therapy
12.3.3. Chemotherapy
12.3.4. Immunotherapy
12.3.5. Targeted Therapy
12.3.6. Hormone Therapy
12.3.7. Stem Cell Transplant
12.3.8. Others
12.4. North America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.4.1. Oral
12.4.2. Intravenous
12.4.3. Subcutaneous
12.4.4. Intrathecal
12.4.5. Intraventricular
12.4.6. Others
12.5. North America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Dosage (mg)
12.5.1. 50 to 100
12.5.2. 200
12.5.3. 500
12.5.4. Others
12.6. North America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Indication
12.6.1.1.1. Blood Cancer
12.6.1.1.2. Breast Cancer
12.6.1.1.3. Prostate Cancer
12.6.1.1.4. Basal Cell Cancer
12.6.1.1.5. Skin Cancer
12.6.1.1.6. Colorectal Cancer
12.6.1.1.7. Lung Cancer
12.6.1.1.8. Renal Cancer
12.6.1.1.9. Bladder Cancer
12.6.1.1.10. Lymphoma
12.6.1.1.11. Others
12.6.1.2. U.S Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.2.1. Drug Therapies
12.6.1.2.1.1. Antimetabolites
12.6.1.2.1.2. Antitumor Antibiotics
12.6.1.2.1.3. Asparagine-Specific Enzymes
12.6.1.2.1.4. Bisphosphonates and Biosimilars
12.6.1.2.1.5. DNA Damaging Agents and Alkylating Agents
12.6.1.2.1.6. Inhibitors
12.6.1.2.1.7. Monoclonal Antibodies
12.6.1.2.1.8. Others
12.6.1.2.2. Radiation Therapy
12.6.1.2.3. Chemotherapy
12.6.1.2.4. Immunotherapy
12.6.1.2.5. Targeted Therapy
12.6.1.2.6. Hormone Therapy
12.6.1.2.7. Stem Cell Transplant
12.6.1.2.8. Others
12.6.1.3. U.S Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.1.3.1. Oral
12.6.1.3.2. Intravenous
12.6.1.3.3. Subcutaneous
12.6.1.3.4. Intrathecal
12.6.1.3.5. Intraventricular
12.6.1.3.6. Others
12.6.1.4. U.S Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Dosage (mg)
12.6.1.4.1. 50 to 100
12.6.1.4.2. 200
12.6.1.4.3. 500
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
12.6.2.1.1. Blood Cancer
12.6.2.1.2. Breast Cancer
12.6.2.1.3. Prostate Cancer
12.6.2.1.4. Basal Cell Cancer
12.6.2.1.5. Skin Cancer
12.6.2.1.6. Colorectal Cancer
12.6.2.1.7. Lung Cancer
12.6.2.1.8. Renal Cancer
12.6.2.1.9. Bladder Cancer
12.6.2.1.10. Lymphoma
12.6.2.1.11. Others
12.6.2.2. Canada Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.2.2.1. Drug Therapies
12.6.2.2.1.1. Antimetabolites
12.6.2.2.1.2. Antitumor Antibiotics
12.6.2.2.1.3. Asparagine-Specific Enzymes
12.6.2.2.1.4. Bisphosphonates and Biosimilars
12.6.2.2.1.5. DNA Damaging Agents and Alkylating Agents
12.6.2.2.1.6. Inhibitors
12.6.2.2.1.7. Monoclonal Antibodies
12.6.2.2.1.8. Others
12.6.2.2.2. Radiation Therapy
12.6.2.2.3. Chemotherapy
12.6.2.2.4. Immunotherapy
12.6.2.2.5. Targeted Therapy
12.6.2.2.6. Hormone Therapy
12.6.2.2.7. Stem Cell Transplant
12.6.2.2.8. Others
12.6.2.3. Canada Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
12.6.2.3.1. Oral
12.6.2.3.2. Intravenous
12.6.2.3.3. Subcutaneous
12.6.2.3.4. Intrathecal
12.6.2.3.5. Intraventricular
12.6.2.3.6. Others
12.6.2.4. Canada Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
12.6.2.4.1. 50 to 100
12.6.2.4.2. 200
12.6.2.4.3. 500
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
12.6.3.1.1. Blood Cancer
12.6.3.1.2. Breast Cancer
12.6.3.1.3. Prostate Cancer
12.6.3.1.4. Basal Cell Cancer
12.6.3.1.5. Skin Cancer
12.6.3.1.6. Colorectal Cancer
12.6.3.1.7. Lung Cancer
12.6.3.1.8. Renal Cancer
12.6.3.1.9. Bladder Cancer
12.6.3.1.10. Lymphoma
12.6.3.1.11. Others
12.6.3.2. Mexico Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.3.2.1. Drug Therapies
12.6.3.2.1.1. Antimetabolites
12.6.3.2.1.2. Antitumor Antibiotics
12.6.3.2.1.3. Asparagine-Specific Enzymes
12.6.3.2.1.4. Bisphosphonates and Biosimilars
12.6.3.2.1.5. DNA Damaging Agents and Alkylating Agents
12.6.3.2.1.6. Inhibitors
12.6.3.2.1.7. Monoclonal Antibodies
12.6.3.2.1.8. Others
12.6.3.2.2. Radiation Therapy
12.6.3.2.3. Chemotherapy
12.6.3.2.4. Immunotherapy
12.6.3.2.5. Targeted Therapy
12.6.3.2.6. Hormone Therapy
12.6.3.2.7. Stem Cell Transplant
12.6.3.2.8. Others
12.6.3.3. Mexico Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Intravenous
12.6.3.3.3. Subcutaneous
12.6.3.3.4. Intrathecal
12.6.3.3.5. Intraventricular
12.6.3.3.6. Others
12.6.3.4. Mexico Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
12.6.3.4.1. 50 to 100
12.6.3.4.2. 200
12.6.3.4.3. 500
12.6.3.4.4. Others
12.6.4. Rest of North America
12.6.4.1. Rest of North America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Indication
12.6.4.1.1. Blood Cancer
12.6.4.1.2. Breast Cancer
12.6.4.1.3. Prostate Cancer
12.6.4.1.4. Basal Cell Cancer
12.6.4.1.5. Skin Cancer
12.6.4.1.6. Colorectal Cancer
12.6.4.1.7. Lung Cancer
12.6.4.1.8. Renal Cancer
12.6.4.1.9. Bladder Cancer
12.6.4.1.10. Lymphoma
12.6.4.1.11. Others
12.6.4.2. Rest of North America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Application
12.6.4.2.1. Drug Therapies
12.6.4.2.1.1. Antimetabolites
12.6.4.2.1.2. Antitumor Antibiotics
12.6.4.2.1.3. Asparagine-Specific Enzymes
12.6.4.2.1.4. Bisphosphonates and Biosimilars
12.6.4.2.1.5. DNA Damaging Agents and Alkylating Agents
12.6.4.2.1.6. Inhibitors
12.6.4.2.1.7. Monoclonal Antibodies
12.6.4.2.1.8. Others
12.6.4.2.2. Radiation Therapy
12.6.4.2.3. Chemotherapy
12.6.4.2.4. Immunotherapy
12.6.4.2.5. Targeted Therapy
12.6.4.2.6. Hormone Therapy
12.6.4.2.7. Stem Cell Transplant
12.6.4.2.8. Others
12.6.4.3. Rest of North America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Intravenous
12.6.4.3.3. Subcutaneous
12.6.4.3.4. Intrathecal
12.6.4.3.5. Intraventricular
12.6.4.3.6. Others
12.6.4.4. Rest of North America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Dosage (mg)
12.6.4.4.1. 50 to 100
12.6.4.4.2. 200
12.6.4.4.3. 500
12.6.4.4.4. Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Indication
12.7.3. By Application
12.7.4. By Route of Administration
12.7.5. By Dosage (mg)
13.
Europe Oncology Pharmaceuticals Market Analysis and
Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe Oncology Pharmaceuticals Market Revenue (US$ Mn)
13.2. Europe Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
13.2.1. Blood Cancer
13.2.2. Breast Cancer
13.2.3. Prostate Cancer
13.2.4. Basal Cell Cancer
13.2.5. Skin Cancer
13.2.6. Colorectal Cancer
13.2.7. Lung Cancer
13.2.8. Renal Cancer
13.2.9. Bladder Cancer
13.2.10. Lymphoma
13.2.11. Others
13.3. Europe Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
13.3.1. Drug Therapies
13.3.1.1. Antimetabolites
13.3.1.2. Antitumor Antibiotics
13.3.1.3. Asparagine-Specific Enzymes
13.3.1.4. Bisphosphonates and Biosimilars
13.3.1.5. DNA Damaging Agents and Alkylating Agents
13.3.1.6. Inhibitors
13.3.1.7. Monoclonal Antibodies
13.3.1.8. Others
13.3.2. Radiation Therapy
13.3.3. Chemotherapy
13.3.4. Immunotherapy
13.3.5. Targeted Therapy
13.3.6. Hormone Therapy
13.3.7. Stem Cell Transplant
13.3.8. Others
13.4. Europe Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.4.1. Oral
13.4.2. Intravenous
13.4.3. Subcutaneous
13.4.4. Intrathecal
13.4.5. Intraventricular
13.4.6. Others
13.5. Europe Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
13.5.1. 50 to 100
13.5.2. 200
13.5.3. 500
13.5.4. Others
13.6. Europe Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.1. France
13.6.1.1. France Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
13.6.1.1.1. Blood Cancer
13.6.1.1.2. Breast Cancer
13.6.1.1.3. Prostate Cancer
13.6.1.1.4. Basal Cell Cancer
13.6.1.1.5. Skin Cancer
13.6.1.1.6. Colorectal Cancer
13.6.1.1.7. Lung Cancer
13.6.1.1.8. Renal Cancer
13.6.1.1.9. Bladder Cancer
13.6.1.1.10. Lymphoma
13.6.1.1.11. Others
13.6.1.2. France Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.1.2.1. Drug Therapies
13.6.1.2.1.1. Antimetabolites
13.6.1.2.1.2. Antitumor Antibiotics
13.6.1.2.1.3. Asparagine-Specific Enzymes
13.6.1.2.1.4. Bisphosphonates and Biosimilars
13.6.1.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.1.2.1.6. Inhibitors
13.6.1.2.1.7. Monoclonal Antibodies
13.6.1.2.1.8. Others
13.6.1.2.2. Radiation Therapy
13.6.1.2.3. Chemotherapy
13.6.1.2.4. Immunotherapy
13.6.1.2.5. Targeted Therapy
13.6.1.2.6. Hormone Therapy
13.6.1.2.7. Stem Cell Transplant
13.6.1.2.8. Others
13.6.1.3. France Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.1.3.1. Oral
13.6.1.3.2. Intravenous
13.6.1.3.3. Subcutaneous
13.6.1.3.4. Intrathecal
13.6.1.3.5. Intraventricular
13.6.1.3.6. Others
13.6.1.4. France Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
13.6.1.4.1. 50 to 100
13.6.1.4.2. 200
13.6.1.4.3. 500
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
13.6.2.1.1. Blood Cancer
13.6.2.1.2. Breast Cancer
13.6.2.1.3. Prostate Cancer
13.6.2.1.4. Basal Cell Cancer
13.6.2.1.5. Skin Cancer
13.6.2.1.6. Colorectal Cancer
13.6.2.1.7. Lung Cancer
13.6.2.1.8. Renal Cancer
13.6.2.1.9. Bladder Cancer
13.6.2.1.10. Lymphoma
13.6.2.1.11. Others
13.6.2.2. The UK Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.2.2.1. Drug Therapies
13.6.2.2.1.1. Antimetabolites
13.6.2.2.1.2. Antitumor Antibiotics
13.6.2.2.1.3. Asparagine-Specific Enzymes
13.6.2.2.1.4. Bisphosphonates and Biosimilars
13.6.2.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.2.2.1.6. Inhibitors
13.6.2.2.1.7. Monoclonal Antibodies
13.6.2.2.1.8. Others
13.6.2.2.2. Radiation Therapy
13.6.2.2.3. Chemotherapy
13.6.2.2.4. Immunotherapy
13.6.2.2.5. Targeted Therapy
13.6.2.2.6. Hormone Therapy
13.6.2.2.7. Stem Cell Transplant
13.6.2.2.8. Others
13.6.2.3. The UK Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.2.3.1. Oral
13.6.2.3.2. Intravenous
13.6.2.3.3. Subcutaneous
13.6.2.3.4. Intrathecal
13.6.2.3.5. Intraventricular
13.6.2.3.6. Others
13.6.2.4. The UK Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
13.6.2.4.1. 50 to 100
13.6.2.4.2. 200
13.6.2.4.3. 500
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
13.6.3.1.1. Blood Cancer
13.6.3.1.2. Breast Cancer
13.6.3.1.3. Prostate Cancer
13.6.3.1.4. Basal Cell Cancer
13.6.3.1.5. Skin Cancer
13.6.3.1.6. Colorectal Cancer
13.6.3.1.7. Lung Cancer
13.6.3.1.8. Renal Cancer
13.6.3.1.9. Bladder Cancer
13.6.3.1.10. Lymphoma
13.6.3.1.11. Others
13.6.3.2. Spain Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.3.2.1. Drug Therapies
13.6.3.2.1.1. Antimetabolites
13.6.3.2.1.2. Antitumor Antibiotics
13.6.3.2.1.3. Asparagine-Specific Enzymes
13.6.3.2.1.4. Bisphosphonates and Biosimilars
13.6.3.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.3.2.1.6. Inhibitors
13.6.3.2.1.7. Monoclonal Antibodies
13.6.3.2.1.8. Others
13.6.3.2.2. Radiation Therapy
13.6.3.2.3. Chemotherapy
13.6.3.2.4. Immunotherapy
13.6.3.2.5. Targeted Therapy
13.6.3.2.6. Hormone Therapy
13.6.3.2.7. Stem Cell Transplant
13.6.3.2.8. Others
13.6.3.3. Spain Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.3.3.1. Oral
13.6.3.3.2. Intravenous
13.6.3.3.3. Subcutaneous
13.6.3.3.4. Intrathecal
13.6.3.3.5. Intraventricular
13.6.3.3.6. Others
13.6.3.4. Spain Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
13.6.3.4.1. 50 to 100
13.6.3.4.2. 200
13.6.3.4.3. 500
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
13.6.4.1.1. Blood Cancer
13.6.4.1.2. Breast Cancer
13.6.4.1.3. Prostate Cancer
13.6.4.1.4. Basal Cell Cancer
13.6.4.1.5. Skin Cancer
13.6.4.1.6. Colorectal Cancer
13.6.4.1.7. Lung Cancer
13.6.4.1.8. Renal Cancer
13.6.4.1.9. Bladder Cancer
13.6.4.1.10. Lymphoma
13.6.4.1.11. Others
13.6.4.2. Germany Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.4.2.1. Drug Therapies
13.6.4.2.1.1. Antimetabolites
13.6.4.2.1.2. Antitumor Antibiotics
13.6.4.2.1.3. Asparagine-Specific Enzymes
13.6.4.2.1.4. Bisphosphonates and Biosimilars
13.6.4.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.4.2.1.6. Inhibitors
13.6.4.2.1.7. Monoclonal Antibodies
13.6.4.2.1.8. Others
13.6.4.2.2. Radiation Therapy
13.6.4.2.3. Chemotherapy
13.6.4.2.4. Immunotherapy
13.6.4.2.5. Targeted Therapy
13.6.4.2.6. Hormone Therapy
13.6.4.2.7. Stem Cell Transplant
13.6.4.2.8. Others
13.6.4.3. Germany Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Intravenous
13.6.4.3.3. Subcutaneous
13.6.4.3.4. Intrathecal
13.6.4.3.5. Intraventricular
13.6.4.3.6. Others
13.6.4.4. Germany Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
13.6.4.4.1. 50 to 100
13.6.4.4.2. 200
13.6.4.4.3. 500
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
13.6.5.1.1. Blood Cancer
13.6.5.1.2. Breast Cancer
13.6.5.1.3. Prostate Cancer
13.6.5.1.4. Basal Cell Cancer
13.6.5.1.5. Skin Cancer
13.6.5.1.6. Colorectal Cancer
13.6.5.1.7. Lung Cancer
13.6.5.1.8. Renal Cancer
13.6.5.1.9. Bladder Cancer
13.6.5.1.10. Lymphoma
13.6.5.1.11. Others
13.6.5.2. Italy Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.5.2.1. Drug Therapies
13.6.5.2.1.1. Antimetabolites
13.6.5.2.1.2. Antitumor Antibiotics
13.6.5.2.1.3. Asparagine-Specific Enzymes
13.6.5.2.1.4. Bisphosphonates and Biosimilars
13.6.5.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.5.2.1.6. Inhibitors
13.6.5.2.1.7. Monoclonal Antibodies
13.6.5.2.1.8. Others
13.6.5.2.2. Radiation Therapy
13.6.5.2.3. Chemotherapy
13.6.5.2.4. Immunotherapy
13.6.5.2.5. Targeted Therapy
13.6.5.2.6. Hormone Therapy
13.6.5.2.7. Stem Cell Transplant
13.6.5.2.8. Others
13.6.5.3. Italy Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Intravenous
13.6.5.3.3. Subcutaneous
13.6.5.3.4. Intrathecal
13.6.5.3.5. Intraventricular
13.6.5.3.6. Others
13.6.5.4. Italy Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
13.6.5.4.1. 50 to 100
13.6.5.4.2. 200
13.6.5.4.3. 500
13.6.5.4.4. Others
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.6.1.1. Blood Cancer
13.6.6.1.2. Breast Cancer
13.6.6.1.3. Prostate Cancer
13.6.6.1.4. Basal Cell Cancer
13.6.6.1.5. Skin Cancer
13.6.6.1.6. Colorectal Cancer
13.6.6.1.7. Lung Cancer
13.6.6.1.8. Renal Cancer
13.6.6.1.9. Bladder Cancer
13.6.6.1.10. Lymphoma
13.6.6.1.11. Others
13.6.6.2. Nordic Countries Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.6.2.1. Drug Therapies
13.6.6.2.1.1. Antimetabolites
13.6.6.2.1.2. Antitumor Antibiotics
13.6.6.2.1.3. Asparagine-Specific Enzymes
13.6.6.2.1.4. Bisphosphonates and Biosimilars
13.6.6.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.6.2.1.6. Inhibitors
13.6.6.2.1.7. Monoclonal Antibodies
13.6.6.2.1.8. Others
13.6.6.2.2. Radiation Therapy
13.6.6.2.3. Chemotherapy
13.6.6.2.4. Immunotherapy
13.6.6.2.5. Targeted Therapy
13.6.6.2.6. Hormone Therapy
13.6.6.2.7. Stem Cell Transplant
13.6.6.2.8. Others
13.6.6.3. Nordic Countries Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.6.3.1. Oral
13.6.6.3.2. Intravenous
13.6.6.3.3. Subcutaneous
13.6.6.3.4. Intrathecal
13.6.6.3.5. Intraventricular
13.6.6.3.6. Others
13.6.6.4. Nordic Countries Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Dosage (mg)
13.6.6.4.1. 50 to 100
13.6.6.4.2. 200
13.6.6.4.3. 500
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.7.1.1. Blood Cancer
13.6.7.1.2. Breast Cancer
13.6.7.1.3. Prostate Cancer
13.6.7.1.4. Basal Cell Cancer
13.6.7.1.5. Skin Cancer
13.6.7.1.6. Colorectal Cancer
13.6.7.1.7. Lung Cancer
13.6.7.1.8. Renal Cancer
13.6.7.1.9. Bladder Cancer
13.6.7.1.10. Lymphoma
13.6.7.1.11. Others
13.6.7.2. Benelux Union Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.7.2.1. Drug Therapies
13.6.7.2.1.1. Antimetabolites
13.6.7.2.1.2. Antitumor Antibiotics
13.6.7.2.1.3. Asparagine-Specific Enzymes
13.6.7.2.1.4. Bisphosphonates and Biosimilars
13.6.7.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.7.2.1.6. Inhibitors
13.6.7.2.1.7. Monoclonal Antibodies
13.6.7.2.1.8. Others
13.6.7.2.2. Radiation Therapy
13.6.7.2.3. Chemotherapy
13.6.7.2.4. Immunotherapy
13.6.7.2.5. Targeted Therapy
13.6.7.2.6. Hormone Therapy
13.6.7.2.7. Stem Cell Transplant
13.6.7.2.8. Others
13.6.7.3. Benelux Union Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.7.3.1. Oral
13.6.7.3.2. Intravenous
13.6.7.3.3. Subcutaneous
13.6.7.3.4. Intrathecal
13.6.7.3.5. Intraventricular
13.6.7.3.6. Others
13.6.7.4. Benelux Union Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Dosage (mg)
13.6.7.4.1. 50 to 100
13.6.7.4.2. 200
13.6.7.4.3. 500
13.6.7.4.4. Others
13.6.7.5. Benelux Union Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Indication
13.6.8.1.1. Blood Cancer
13.6.8.1.2. Breast Cancer
13.6.8.1.3. Prostate Cancer
13.6.8.1.4. Basal Cell Cancer
13.6.8.1.5. Skin Cancer
13.6.8.1.6. Colorectal Cancer
13.6.8.1.7. Lung Cancer
13.6.8.1.8. Renal Cancer
13.6.8.1.9. Bladder Cancer
13.6.8.1.10. Lymphoma
13.6.8.1.11. Others
13.6.8.2. Rest of Europe Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.8.2.1. Drug Therapies
13.6.8.2.1.1. Antimetabolites
13.6.8.2.1.2. Antitumor Antibiotics
13.6.8.2.1.3. Asparagine-Specific Enzymes
13.6.8.2.1.4. Bisphosphonates and Biosimilars
13.6.8.2.1.5. DNA Damaging Agents and Alkylating Agents
13.6.8.2.1.6. Inhibitors
13.6.8.2.1.7. Monoclonal Antibodies
13.6.8.2.1.8. Others
13.6.8.2.2. Radiation Therapy
13.6.8.2.3. Chemotherapy
13.6.8.2.4. Immunotherapy
13.6.8.2.5. Targeted Therapy
13.6.8.2.6. Hormone Therapy
13.6.8.2.7. Stem Cell Transplant
13.6.8.2.8. Others
13.6.8.3. Rest of Europe Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.6.8.3.1. Oral
13.6.8.3.2. Intravenous
13.6.8.3.3. Subcutaneous
13.6.8.3.4. Intrathecal
13.6.8.3.5. Intraventricular
13.6.8.3.6. Others
13.6.8.4. Rest of Europe Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Dosage (mg)
13.6.8.4.1. 50 to 100
13.6.8.4.2. 200
13.6.8.4.3. 500
13.6.8.4.4. Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Indication
13.7.3. By Application
13.7.4. By Route of Administration
13.7.5. By Dosage (mg)
14.
Asia Pacific Oncology Pharmaceuticals Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Oncology Pharmaceuticals Market Revenue (US$
Mn)
14.2. Asia Pacific Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
14.2.1. Blood Cancer
14.2.2. Breast Cancer
14.2.3. Prostate Cancer
14.2.4. Basal Cell Cancer
14.2.5. Skin Cancer
14.2.6. Colorectal Cancer
14.2.7. Lung Cancer
14.2.8. Renal Cancer
14.2.9. Bladder Cancer
14.2.10. Lymphoma
14.2.11. Others
14.3. Asia Pacific Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
14.3.1. Drug Therapies
14.3.1.1. Antimetabolites
14.3.1.2. Antitumor Antibiotics
14.3.1.3. Asparagine-Specific Enzymes
14.3.1.4. Bisphosphonates and Biosimilars
14.3.1.5. DNA Damaging Agents and Alkylating Agents
14.3.1.6. Inhibitors
14.3.1.7. Monoclonal Antibodies
14.3.1.8. Others
14.3.2. Radiation Therapy
14.3.3. Chemotherapy
14.3.4. Immunotherapy
14.3.5. Targeted Therapy
14.3.6. Hormone Therapy
14.3.7. Stem Cell Transplant
14.3.8. Others
14.4. Asia Pacific Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.4.1. Oral
14.4.2. Intravenous
14.4.3. Subcutaneous
14.4.4. Intrathecal
14.4.5. Intraventricular
14.4.6. Others
14.5. Asia Pacific Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
14.5.1. 50 to 100
14.5.2. 200
14.5.3. 500
14.5.4. Others
14.6. Asia Pacific Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
14.6.1.1.1. Blood Cancer
14.6.1.1.2. Breast Cancer
14.6.1.1.3. Prostate Cancer
14.6.1.1.4. Basal Cell Cancer
14.6.1.1.5. Skin Cancer
14.6.1.1.6. Colorectal Cancer
14.6.1.1.7. Lung Cancer
14.6.1.1.8. Renal Cancer
14.6.1.1.9. Bladder Cancer
14.6.1.1.10. Lymphoma
14.6.1.1.11. Others
14.6.1.2. China Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.1.2.1. Drug Therapies
14.6.1.2.1.1. Antimetabolites
14.6.1.2.1.2. Antitumor Antibiotics
14.6.1.2.1.3. Asparagine-Specific Enzymes
14.6.1.2.1.4. Bisphosphonates and Biosimilars
14.6.1.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.1.2.1.6. Inhibitors
14.6.1.2.1.7. Monoclonal Antibodies
14.6.1.2.1.8. Others
14.6.1.2.2. Radiation Therapy
14.6.1.2.3. Chemotherapy
14.6.1.2.4. Immunotherapy
14.6.1.2.5. Targeted Therapy
14.6.1.2.6. Hormone Therapy
14.6.1.2.7. Stem Cell Transplant
14.6.1.2.8. Others
14.6.1.3. China Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Intravenous
14.6.1.3.3. Subcutaneous
14.6.1.3.4. Intrathecal
14.6.1.3.5. Intraventricular
14.6.1.3.6. Others
14.6.1.4. China Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
14.6.1.4.1. 50 to 100
14.6.1.4.2. 200
14.6.1.4.3. 500
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
14.6.2.1.1. Blood Cancer
14.6.2.1.2. Breast Cancer
14.6.2.1.3. Prostate Cancer
14.6.2.1.4. Basal Cell Cancer
14.6.2.1.5. Skin Cancer
14.6.2.1.6. Colorectal Cancer
14.6.2.1.7. Lung Cancer
14.6.2.1.8. Renal Cancer
14.6.2.1.9. Bladder Cancer
14.6.2.1.10. Lymphoma
14.6.2.1.11. Others
14.6.2.2. Japan Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.2.2.1. Drug Therapies
14.6.2.2.1.1. Antimetabolites
14.6.2.2.1.2. Antitumor Antibiotics
14.6.2.2.1.3. Asparagine-Specific Enzymes
14.6.2.2.1.4. Bisphosphonates and Biosimilars
14.6.2.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.2.2.1.6. Inhibitors
14.6.2.2.1.7. Monoclonal Antibodies
14.6.2.2.1.8. Others
14.6.2.2.2. Radiation Therapy
14.6.2.2.3. Chemotherapy
14.6.2.2.4. Immunotherapy
14.6.2.2.5. Targeted Therapy
14.6.2.2.6. Hormone Therapy
14.6.2.2.7. Stem Cell Transplant
14.6.2.2.8. Others
14.6.2.3. Japan Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Intravenous
14.6.2.3.3. Subcutaneous
14.6.2.3.4. Intrathecal
14.6.2.3.5. Intraventricular
14.6.2.3.6. Others
14.6.2.4. Japan Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
14.6.2.4.1. 50 to 100
14.6.2.4.2. 200
14.6.2.4.3. 500
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
14.6.3.1.1. Blood Cancer
14.6.3.1.2. Breast Cancer
14.6.3.1.3. Prostate Cancer
14.6.3.1.4. Basal Cell Cancer
14.6.3.1.5. Skin Cancer
14.6.3.1.6. Colorectal Cancer
14.6.3.1.7. Lung Cancer
14.6.3.1.8. Renal Cancer
14.6.3.1.9. Bladder Cancer
14.6.3.1.10. Lymphoma
14.6.3.1.11. Others
14.6.3.2. India Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.3.2.1. Drug Therapies
14.6.3.2.1.1. Antimetabolites
14.6.3.2.1.2. Antitumor Antibiotics
14.6.3.2.1.3. Asparagine-Specific Enzymes
14.6.3.2.1.4. Bisphosphonates and Biosimilars
14.6.3.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.3.2.1.6. Inhibitors
14.6.3.2.1.7. Monoclonal Antibodies
14.6.3.2.1.8. Others
14.6.3.2.2. Radiation Therapy
14.6.3.2.3. Chemotherapy
14.6.3.2.4. Immunotherapy
14.6.3.2.5. Targeted Therapy
14.6.3.2.6. Hormone Therapy
14.6.3.2.7. Stem Cell Transplant
14.6.3.2.8. Others
14.6.3.3. India Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Intravenous
14.6.3.3.3. Subcutaneous
14.6.3.3.4. Intrathecal
14.6.3.3.5. Intraventricular
14.6.3.3.6. Others
14.6.3.4. India Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
14.6.3.4.1. 50 to 100
14.6.3.4.2. 200
14.6.3.4.3. 500
14.6.3.4.4. Others
14.6.4. New Zealand
14.6.4.1. New Zealand Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
14.6.4.1.1. Blood Cancer
14.6.4.1.2. Breast Cancer
14.6.4.1.3. Prostate Cancer
14.6.4.1.4. Basal Cell Cancer
14.6.4.1.5. Skin Cancer
14.6.4.1.6. Colorectal Cancer
14.6.4.1.7. Lung Cancer
14.6.4.1.8. Renal Cancer
14.6.4.1.9. Bladder Cancer
14.6.4.1.10. Lymphoma
14.6.4.1.11. Others
14.6.4.2. New Zealand Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
14.6.4.2.1. Drug Therapies
14.6.4.2.1.1. Antimetabolites
14.6.4.2.1.2. Antitumor Antibiotics
14.6.4.2.1.3. Asparagine-Specific Enzymes
14.6.4.2.1.4. Bisphosphonates and Biosimilars
14.6.4.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.4.2.1.6. Inhibitors
14.6.4.2.1.7. Monoclonal Antibodies
14.6.4.2.1.8. Others
14.6.4.2.2. Radiation Therapy
14.6.4.2.3. Chemotherapy
14.6.4.2.4. Immunotherapy
14.6.4.2.5. Targeted Therapy
14.6.4.2.6. Hormone Therapy
14.6.4.2.7. Stem Cell Transplant
14.6.4.2.8. Others
14.6.4.3. New Zealand Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Intravenous
14.6.4.3.3. Subcutaneous
14.6.4.3.4. Intrathecal
14.6.4.3.5. Intraventricular
14.6.4.3.6. Others
14.6.4.4. New Zealand Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
14.6.4.4.1. 50 to 100
14.6.4.4.2. 200
14.6.4.4.3. 500
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
14.6.5.1.1. Blood Cancer
14.6.5.1.2. Breast Cancer
14.6.5.1.3. Prostate Cancer
14.6.5.1.4. Basal Cell Cancer
14.6.5.1.5. Skin Cancer
14.6.5.1.6. Colorectal Cancer
14.6.5.1.7. Lung Cancer
14.6.5.1.8. Renal Cancer
14.6.5.1.9. Bladder Cancer
14.6.5.1.10. Lymphoma
14.6.5.1.11. Others
14.6.5.2. Australia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
14.6.5.2.1. Drug Therapies
14.6.5.2.1.1. Antimetabolites
14.6.5.2.1.2. Antitumor Antibiotics
14.6.5.2.1.3. Asparagine-Specific Enzymes
14.6.5.2.1.4. Bisphosphonates and Biosimilars
14.6.5.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.5.2.1.6. Inhibitors
14.6.5.2.1.7. Monoclonal Antibodies
14.6.5.2.1.8. Others
14.6.5.2.2. Radiation Therapy
14.6.5.2.3. Chemotherapy
14.6.5.2.4. Immunotherapy
14.6.5.2.5. Targeted Therapy
14.6.5.2.6. Hormone Therapy
14.6.5.2.7. Stem Cell Transplant
14.6.5.2.8. Others
14.6.5.3. Australia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Intravenous
14.6.5.3.3. Subcutaneous
14.6.5.3.4. Intrathecal
14.6.5.3.5. Intraventricular
14.6.5.3.6. Others
14.6.5.4. Australia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
14.6.5.4.1. 50 to 100
14.6.5.4.2. 200
14.6.5.4.3. 500
14.6.5.4.4. Others
14.6.6. South Korea
14.6.6.1. South Korea Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
14.6.6.1.1. Blood Cancer
14.6.6.1.2. Breast Cancer
14.6.6.1.3. Prostate Cancer
14.6.6.1.4. Basal Cell Cancer
14.6.6.1.5. Skin Cancer
14.6.6.1.6. Colorectal Cancer
14.6.6.1.7. Lung Cancer
14.6.6.1.8. Renal Cancer
14.6.6.1.9. Bladder Cancer
14.6.6.1.10. Lymphoma
14.6.6.1.11. Others
14.6.6.2. South Korea Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
14.6.6.2.1. Drug Therapies
14.6.6.2.1.1. Antimetabolites
14.6.6.2.1.2. Antitumor Antibiotics
14.6.6.2.1.3. Asparagine-Specific Enzymes
14.6.6.2.1.4. Bisphosphonates and Biosimilars
14.6.6.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.6.2.1.6. Inhibitors
14.6.6.2.1.7. Monoclonal Antibodies
14.6.6.2.1.8. Others
14.6.6.2.2. Radiation Therapy
14.6.6.2.3. Chemotherapy
14.6.6.2.4. Immunotherapy
14.6.6.2.5. Targeted Therapy
14.6.6.2.6. Hormone Therapy
14.6.6.2.7. Stem Cell Transplant
14.6.6.2.8. Others
14.6.6.3. South Korea Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Intravenous
14.6.6.3.3. Subcutaneous
14.6.6.3.4. Intrathecal
14.6.6.3.5. Intraventricular
14.6.6.3.6. Others
14.6.6.4. South Korea Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
14.6.6.4.1. 50 to 100
14.6.6.4.2. 200
14.6.6.4.3. 500
14.6.6.4.4. Others
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Indication
14.6.7.1.1. Blood Cancer
14.6.7.1.2. Breast Cancer
14.6.7.1.3. Prostate Cancer
14.6.7.1.4. Basal Cell Cancer
14.6.7.1.5. Skin Cancer
14.6.7.1.6. Colorectal Cancer
14.6.7.1.7. Lung Cancer
14.6.7.1.8. Renal Cancer
14.6.7.1.9. Bladder Cancer
14.6.7.1.10. Lymphoma
14.6.7.1.11. Others
14.6.7.2. Southeast Asia Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.7.2.1. Drug Therapies
14.6.7.2.1.1. Antimetabolites
14.6.7.2.1.2. Antitumor Antibiotics
14.6.7.2.1.3. Asparagine-Specific Enzymes
14.6.7.2.1.4. Bisphosphonates and Biosimilars
14.6.7.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.7.2.1.6. Inhibitors
14.6.7.2.1.7. Monoclonal Antibodies
14.6.7.2.1.8. Others
14.6.7.2.2. Radiation Therapy
14.6.7.2.3. Chemotherapy
14.6.7.2.4. Immunotherapy
14.6.7.2.5. Targeted Therapy
14.6.7.2.6. Hormone Therapy
14.6.7.2.7. Stem Cell Transplant
14.6.7.2.8. Others
14.6.7.3. Southeast Asia Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.7.3.1. Oral
14.6.7.3.2. Intravenous
14.6.7.3.3. Subcutaneous
14.6.7.3.4. Intrathecal
14.6.7.3.5. Intraventricular
14.6.7.3.6. Others
14.6.7.4. Southeast Asia Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Dosage (mg)
14.6.7.4.1. 50 to 100
14.6.7.4.2. 200
14.6.7.4.3. 500
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Indication
14.6.8.1.1. Blood Cancer
14.6.8.1.2. Breast Cancer
14.6.8.1.3. Prostate Cancer
14.6.8.1.4. Basal Cell Cancer
14.6.8.1.5. Skin Cancer
14.6.8.1.6. Colorectal Cancer
14.6.8.1.7. Lung Cancer
14.6.8.1.8. Renal Cancer
14.6.8.1.9. Bladder Cancer
14.6.8.1.10. Lymphoma
14.6.8.1.11. Others
14.6.8.2. Rest of Asia Pacific Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.8.2.1. Drug Therapies
14.6.8.2.1.1. Antimetabolites
14.6.8.2.1.2. Antitumor Antibiotics
14.6.8.2.1.3. Asparagine-Specific Enzymes
14.6.8.2.1.4. Bisphosphonates and Biosimilars
14.6.8.2.1.5. DNA Damaging Agents and Alkylating Agents
14.6.8.2.1.6. Inhibitors
14.6.8.2.1.7. Monoclonal Antibodies
14.6.8.2.1.8. Others
14.6.8.2.2. Radiation Therapy
14.6.8.2.3. Chemotherapy
14.6.8.2.4. Immunotherapy
14.6.8.2.5. Targeted Therapy
14.6.8.2.6. Hormone Therapy
14.6.8.2.7. Stem Cell Transplant
14.6.8.2.8. Others
14.6.8.3. Rest of Asia Pacific Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.6.8.3.1. Oral
14.6.8.3.2. Intravenous
14.6.8.3.3. Subcutaneous
14.6.8.3.4. Intrathecal
14.6.8.3.5. Intraventricular
14.6.8.3.6. Others
14.6.8.4. Rest of Asia Pacific Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Dosage (mg)
14.6.8.4.1. 50 to 100
14.6.8.4.2. 200
14.6.8.4.3. 500
14.6.8.4.4. Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Indication
14.7.3. By Application
14.7.4. By Route of Administration
14.7.5. By Dosage (mg)
15.
Middle East and Africa Oncology Pharmaceuticals Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle East and Africa Oncology Pharmaceuticals Market
Revenue (US$ Mn)
15.2. Middle East and Africa Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Indication
15.2.1. Blood Cancer
15.2.2. Breast Cancer
15.2.3. Prostate Cancer
15.2.4. Basal Cell Cancer
15.2.5. Skin Cancer
15.2.6. Colorectal Cancer
15.2.7. Lung Cancer
15.2.8. Renal Cancer
15.2.9. Bladder Cancer
15.2.10. Lymphoma
15.2.11. Others
15.3. Middle East and Africa Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Drug Therapies
15.3.1.1. Antimetabolites
15.3.1.2. Antitumor Antibiotics
15.3.1.3. Asparagine-Specific Enzymes
15.3.1.4. Bisphosphonates and Biosimilars
15.3.1.5. DNA Damaging Agents and Alkylating Agents
15.3.1.6. Inhibitors
15.3.1.7. Monoclonal Antibodies
15.3.1.8. Others
15.3.2. Radiation Therapy
15.3.3. Chemotherapy
15.3.4. Immunotherapy
15.3.5. Targeted Therapy
15.3.6. Hormone Therapy
15.3.7. Stem Cell Transplant
15.3.8. Others
15.4. Middle East and Africa Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.4.1. Oral
15.4.2. Intravenous
15.4.3. Subcutaneous
15.4.4. Intrathecal
15.4.5. Intraventricular
15.4.6. Others
15.5. Middle East and Africa Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Dosage (mg)
15.5.1. 50 to 100
15.5.2. 200
15.5.3. 500
15.5.4. Others
15.6. Middle East and Africa Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
15.6.1.1.1. Blood Cancer
15.6.1.1.2. Breast Cancer
15.6.1.1.3. Prostate Cancer
15.6.1.1.4. Basal Cell Cancer
15.6.1.1.5. Skin Cancer
15.6.1.1.6. Colorectal Cancer
15.6.1.1.7. Lung Cancer
15.6.1.1.8. Renal Cancer
15.6.1.1.9. Bladder Cancer
15.6.1.1.10. Lymphoma
15.6.1.1.11. Others
15.6.1.2. Saudi Arabia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
15.6.1.2.1. Drug Therapies
15.6.1.2.1.1. Antimetabolites
15.6.1.2.1.2. Antitumor Antibiotics
15.6.1.2.1.3. Asparagine-Specific Enzymes
15.6.1.2.1.4. Bisphosphonates and Biosimilars
15.6.1.2.1.5. DNA Damaging Agents and Alkylating Agents
15.6.1.2.1.6. Inhibitors
15.6.1.2.1.7. Monoclonal Antibodies
15.6.1.2.1.8. Others
15.6.1.2.2. Radiation Therapy
15.6.1.2.3. Chemotherapy
15.6.1.2.4. Immunotherapy
15.6.1.2.5. Targeted Therapy
15.6.1.2.6. Hormone Therapy
15.6.1.2.7. Stem Cell Transplant
15.6.1.2.8. Others
15.6.1.3. Saudi Arabia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Intravenous
15.6.1.3.3. Subcutaneous
15.6.1.3.4. Intrathecal
15.6.1.3.5. Intraventricular
15.6.1.3.6. Others
15.6.1.4. Saudi Arabia Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
15.6.1.4.1. 50 to 100
15.6.1.4.2. 200
15.6.1.4.3. 500
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Indication
15.6.2.1.1. Blood Cancer
15.6.2.1.2. Breast Cancer
15.6.2.1.3. Prostate Cancer
15.6.2.1.4. Basal Cell Cancer
15.6.2.1.5. Skin Cancer
15.6.2.1.6. Colorectal Cancer
15.6.2.1.7. Lung Cancer
15.6.2.1.8. Renal Cancer
15.6.2.1.9. Bladder Cancer
15.6.2.1.10. Lymphoma
15.6.2.1.11. Others
15.6.2.2. UAE Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.2.2.1. Drug Therapies
15.6.2.2.1.1. Antimetabolites
15.6.2.2.1.2. Antitumor Antibiotics
15.6.2.2.1.3. Asparagine-Specific Enzymes
15.6.2.2.1.4. Bisphosphonates and Biosimilars
15.6.2.2.1.5. DNA Damaging Agents and Alkylating Agents
15.6.2.2.1.6. Inhibitors
15.6.2.2.1.7. Monoclonal Antibodies
15.6.2.2.1.8. Others
15.6.2.2.2. Radiation Therapy
15.6.2.2.3. Chemotherapy
15.6.2.2.4. Immunotherapy
15.6.2.2.5. Targeted Therapy
15.6.2.2.6. Hormone Therapy
15.6.2.2.7. Stem Cell Transplant
15.6.2.2.8. Others
15.6.2.3. UAE Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Intravenous
15.6.2.3.3. Subcutaneous
15.6.2.3.4. Intrathecal
15.6.2.3.5. Intraventricular
15.6.2.3.6. Others
15.6.2.4. UAE Oncology Pharmaceuticals Market Revenue (US$ Mn) and
Forecasts, By Dosage (mg)
15.6.2.4.1. 50 to 100
15.6.2.4.2. 200
15.6.2.4.3. 500
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
15.6.3.1.1. Blood Cancer
15.6.3.1.2. Breast Cancer
15.6.3.1.3. Prostate Cancer
15.6.3.1.4. Basal Cell Cancer
15.6.3.1.5. Skin Cancer
15.6.3.1.6. Colorectal Cancer
15.6.3.1.7. Lung Cancer
15.6.3.1.8. Renal Cancer
15.6.3.1.9. Bladder Cancer
15.6.3.1.10. Lymphoma
15.6.3.1.11. Others
15.6.3.2. Egypt Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.3.2.1. Drug Therapies
15.6.3.2.1.1. Antimetabolites
15.6.3.2.1.2. Antitumor Antibiotics
15.6.3.2.1.3. Asparagine-Specific Enzymes
15.6.3.2.1.4. Bisphosphonates and Biosimilars
15.6.3.2.1.5. DNA Damaging Agents and Alkylating Agents
15.6.3.2.1.6. Inhibitors
15.6.3.2.1.7. Monoclonal Antibodies
15.6.3.2.1.8. Others
15.6.3.2.2. Radiation Therapy
15.6.3.2.3. Chemotherapy
15.6.3.2.4. Immunotherapy
15.6.3.2.5. Targeted Therapy
15.6.3.2.6. Hormone Therapy
15.6.3.2.7. Stem Cell Transplant
15.6.3.2.8. Others
15.6.3.3. Egypt Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.3.3.1. Oral
15.6.3.3.2. Intravenous
15.6.3.3.3. Subcutaneous
15.6.3.3.4. Intrathecal
15.6.3.3.5. Intraventricular
15.6.3.3.6. Others
15.6.3.4. Egypt Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
15.6.3.4.1. 50 to 100
15.6.3.4.2. 200
15.6.3.4.3. 500
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
15.6.4.1.1. Blood Cancer
15.6.4.1.2. Breast Cancer
15.6.4.1.3. Prostate Cancer
15.6.4.1.4. Basal Cell Cancer
15.6.4.1.5. Skin Cancer
15.6.4.1.6. Colorectal Cancer
15.6.4.1.7. Lung Cancer
15.6.4.1.8. Renal Cancer
15.6.4.1.9. Bladder Cancer
15.6.4.1.10. Lymphoma
15.6.4.1.11. Others
15.6.4.2. Kuwait Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.4.2.1. Drug Therapies
15.6.4.2.1.1. Antimetabolites
15.6.4.2.1.2. Antitumor Antibiotics
15.6.4.2.1.3. Asparagine-Specific Enzymes
15.6.4.2.1.4. Bisphosphonates and Biosimilars
15.6.4.2.1.5. DNA Damaging Agents and Alkylating Agents
15.6.4.2.1.6. Inhibitors
15.6.4.2.1.7. Monoclonal Antibodies
15.6.4.2.1.8. Others
15.6.4.2.2. Radiation Therapy
15.6.4.2.3. Chemotherapy
15.6.4.2.4. Immunotherapy
15.6.4.2.5. Targeted Therapy
15.6.4.2.6. Hormone Therapy
15.6.4.2.7. Stem Cell Transplant
15.6.4.2.8. Others
15.6.4.3. Kuwait Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.4.3.1. Oral
15.6.4.3.2. Intravenous
15.6.4.3.3. Subcutaneous
15.6.4.3.4. Intrathecal
15.6.4.3.5. Intraventricular
15.6.4.3.6. Others
15.6.4.4. Kuwait Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
15.6.4.4.1. 50 to 100
15.6.4.4.2. 200
15.6.4.4.3. 500
15.6.4.4.4. Others
15.6.5. South Africa
15.6.5.1. South Africa Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
15.6.5.1.1. Blood Cancer
15.6.5.1.2. Breast Cancer
15.6.5.1.3. Prostate Cancer
15.6.5.1.4. Basal Cell Cancer
15.6.5.1.5. Skin Cancer
15.6.5.1.6. Colorectal Cancer
15.6.5.1.7. Lung Cancer
15.6.5.1.8. Renal Cancer
15.6.5.1.9. Bladder Cancer
15.6.5.1.10. Lymphoma
15.6.5.1.11. Others
15.6.5.2. South Africa Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
15.6.5.2.1. Drug Therapies
15.6.5.2.1.1. Antimetabolites
15.6.5.2.1.2. Antitumor Antibiotics
15.6.5.2.1.3. Asparagine-Specific Enzymes
15.6.5.2.1.4. Bisphosphonates and Biosimilars
15.6.5.2.1.5. DNA Damaging Agents and Alkylating Agents
15.6.5.2.1.6. Inhibitors
15.6.5.2.1.7. Monoclonal Antibodies
15.6.5.2.1.8. Others
15.6.5.2.2. Radiation Therapy
15.6.5.2.3. Chemotherapy
15.6.5.2.4. Immunotherapy
15.6.5.2.5. Targeted Therapy
15.6.5.2.6. Hormone Therapy
15.6.5.2.7. Stem Cell Transplant
15.6.5.2.8. Others
15.6.5.3. South Africa Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
15.6.5.3.1. Oral
15.6.5.3.2. Intravenous
15.6.5.3.3. Subcutaneous
15.6.5.3.4. Intrathecal
15.6.5.3.5. Intraventricular
15.6.5.3.6. Others
15.6.5.4. South Africa Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
15.6.5.4.1. 50 to 100
15.6.5.4.2. 200
15.6.5.4.3. 500
15.6.5.4.4. Others
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Oncology Pharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Indication
15.6.6.1.1. Blood Cancer
15.6.6.1.2. Breast Cancer
15.6.6.1.3. Prostate Cancer
15.6.6.1.4. Basal Cell Cancer
15.6.6.1.5. Skin Cancer
15.6.6.1.6. Colorectal Cancer
15.6.6.1.7. Lung Cancer
15.6.6.1.8. Renal Cancer
15.6.6.1.9. Bladder Cancer
15.6.6.1.10. Lymphoma
15.6.6.1.11. Others
15.6.6.2. Rest of Middle East & Africa Oncology Pharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.2.1. Drug Therapies
15.6.6.2.1.1. Antimetabolites
15.6.6.2.1.2. Antitumor Antibiotics
15.6.6.2.1.3. Asparagine-Specific Enzymes
15.6.6.2.1.4. Bisphosphonates and Biosimilars
15.6.6.2.1.5. DNA Damaging Agents and Alkylating Agents
15.6.6.2.1.6. Inhibitors
15.6.6.2.1.7. Monoclonal Antibodies
15.6.6.2.1.8. Others
15.6.6.2.2. Radiation Therapy
15.6.6.2.3. Chemotherapy
15.6.6.2.4. Immunotherapy
15.6.6.2.5. Targeted Therapy
15.6.6.2.6. Hormone Therapy
15.6.6.2.7. Stem Cell Transplant
15.6.6.2.8. Others
15.6.6.3. Rest of Middle East & Africa Oncology Pharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.3.1. Oral
15.6.6.3.2. Intravenous
15.6.6.3.3. Subcutaneous
15.6.6.3.4. Intrathecal
15.6.6.3.5. Intraventricular
15.6.6.3.6. Others
15.6.6.4. Rest of Middle East & Africa Oncology Pharmaceuticals
Market Revenue (US$ Mn) and Forecasts, By Dosage (mg)
15.6.6.4.1. 50 to 100
15.6.6.4.2. 200
15.6.6.4.3. 500
15.6.6.4.4. Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Indication
15.7.3. By Application
15.7.4. By Route of Administration
15.7.5. By Dosage (mg)
16.
Latin America Oncology Pharmaceuticals Market Analysis
and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Oncology Pharmaceuticals Market Revenue
(US$ Mn)
16.2. Latin America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Indication
16.2.1. Blood Cancer
16.2.2. Breast Cancer
16.2.3. Prostate Cancer
16.2.4. Basal Cell Cancer
16.2.5. Skin Cancer
16.2.6. Colorectal Cancer
16.2.7. Lung Cancer
16.2.8. Renal Cancer
16.2.9. Bladder Cancer
16.2.10. Lymphoma
16.2.11. Others
16.3. Latin America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Application
16.3.1. Drug Therapies
16.3.1.1. Antimetabolites
16.3.1.2. Antitumor Antibiotics
16.3.1.3. Asparagine-Specific Enzymes
16.3.1.4. Bisphosphonates and Biosimilars
16.3.1.5. DNA Damaging Agents and Alkylating Agents
16.3.1.6. Inhibitors
16.3.1.7. Monoclonal Antibodies
16.3.1.8. Others
16.3.2. Radiation Therapy
16.3.3. Chemotherapy
16.3.4. Immunotherapy
16.3.5. Targeted Therapy
16.3.6. Hormone Therapy
16.3.7. Stem Cell Transplant
16.3.8. Others
16.4. Latin America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.4.1. Oral
16.4.2. Intravenous
16.4.3. Subcutaneous
16.4.4. Intrathecal
16.4.5. Intraventricular
16.4.6. Others
16.5. Latin America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Dosage (mg)
16.5.1. 50 to 100
16.5.2. 200
16.5.3. 500
16.5.4. Others
16.6. Latin America Oncology Pharmaceuticals Market Revenue
(US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Indication
16.6.1.1.1. Blood Cancer
16.6.1.1.2. Breast Cancer
16.6.1.1.3. Prostate Cancer
16.6.1.1.4. Basal Cell Cancer
16.6.1.1.5. Skin Cancer
16.6.1.1.6. Colorectal Cancer
16.6.1.1.7. Lung Cancer
16.6.1.1.8. Renal Cancer
16.6.1.1.9. Bladder Cancer
16.6.1.1.10. Lymphoma
16.6.1.1.11. Others
16.6.1.2. Brazil Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Application
16.6.1.2.1. Drug Therapies
16.6.1.2.1.1. Antimetabolites
16.6.1.2.1.2. Antitumor Antibiotics
16.6.1.2.1.3. Asparagine-Specific Enzymes
16.6.1.2.1.4. Bisphosphonates and Biosimilars
16.6.1.2.1.5. DNA Damaging Agents and Alkylating Agents
16.6.1.2.1.6. Inhibitors
16.6.1.2.1.7. Monoclonal Antibodies
16.6.1.2.1.8. Others
16.6.1.2.2. Radiation Therapy
16.6.1.2.3. Chemotherapy
16.6.1.2.4. Immunotherapy
16.6.1.2.5. Targeted Therapy
16.6.1.2.6. Hormone Therapy
16.6.1.2.7. Stem Cell Transplant
16.6.1.2.8. Others
16.6.1.3. Brazil Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
16.6.1.3.1. Oral
16.6.1.3.2. Intravenous
16.6.1.3.3. Subcutaneous
16.6.1.3.4. Intrathecal
16.6.1.3.5. Intraventricular
16.6.1.3.6. Others
16.6.1.4. Brazil Oncology Pharmaceuticals Market Revenue (US$ Mn)
and Forecasts, By Dosage (mg)
16.6.1.4.1. 50 to 100
16.6.1.4.2. 200
16.6.1.4.3. 500
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Indication
16.6.2.1.1. Blood Cancer
16.6.2.1.2. Breast Cancer
16.6.2.1.3. Prostate Cancer
16.6.2.1.4. Basal Cell Cancer
16.6.2.1.5. Skin Cancer
16.6.2.1.6. Colorectal Cancer
16.6.2.1.7. Lung Cancer
16.6.2.1.8. Renal Cancer
16.6.2.1.9. Bladder Cancer
16.6.2.1.10. Lymphoma
16.6.2.1.11. Others
16.6.2.2. Argentina Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Application
16.6.2.2.1. Drug Therapies
16.6.2.2.1.1. Antimetabolites
16.6.2.2.1.2. Antitumor Antibiotics
16.6.2.2.1.3. Asparagine-Specific Enzymes
16.6.2.2.1.4. Bisphosphonates and Biosimilars
16.6.2.2.1.5. DNA Damaging Agents and Alkylating Agents
16.6.2.2.1.6. Inhibitors
16.6.2.2.1.7. Monoclonal Antibodies
16.6.2.2.1.8. Others
16.6.2.2.2. Radiation Therapy
16.6.2.2.3. Chemotherapy
16.6.2.2.4. Immunotherapy
16.6.2.2.5. Targeted Therapy
16.6.2.2.6. Hormone Therapy
16.6.2.2.7. Stem Cell Transplant
16.6.2.2.8. Others
16.6.2.3. Argentina Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.6.2.3.1. Oral
16.6.2.3.2. Intravenous
16.6.2.3.3. Subcutaneous
16.6.2.3.4. Intrathecal
16.6.2.3.5. Intraventricular
16.6.2.3.6. Others
16.6.2.4. Argentina Oncology Pharmaceuticals Market Revenue (US$
Mn) and Forecasts, By Dosage (mg)
16.6.2.4.1. 50 to 100
16.6.2.4.2. 200
16.6.2.4.3. 500
16.6.2.4.4. Others
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Indication
16.6.3.1.1. Blood Cancer
16.6.3.1.2. Breast Cancer
16.6.3.1.3. Prostate Cancer
16.6.3.1.4. Basal Cell Cancer
16.6.3.1.5. Skin Cancer
16.6.3.1.6. Colorectal Cancer
16.6.3.1.7. Lung Cancer
16.6.3.1.8. Renal Cancer
16.6.3.1.9. Bladder Cancer
16.6.3.1.10. Lymphoma
16.6.3.1.11. Others
16.6.3.2. Rest of Latin America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Application
16.6.3.2.1. Drug Therapies
16.6.3.2.1.1. Antimetabolites
16.6.3.2.1.2. Antitumor Antibiotics
16.6.3.2.1.3. Asparagine-Specific Enzymes
16.6.3.2.1.4. Bisphosphonates and Biosimilars
16.6.3.2.1.5. DNA Damaging Agents and Alkylating Agents
16.6.3.2.1.6. Inhibitors
16.6.3.2.1.7. Monoclonal Antibodies
16.6.3.2.1.8. Others
16.6.3.2.2. Radiation Therapy
16.6.3.2.3. Chemotherapy
16.6.3.2.4. Immunotherapy
16.6.3.2.5. Targeted Therapy
16.6.3.2.6. Hormone Therapy
16.6.3.2.7. Stem Cell Transplant
16.6.3.2.8. Others
16.6.3.3. Rest of Latin America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.6.3.3.1. Oral
16.6.3.3.2. Intravenous
16.6.3.3.3. Subcutaneous
16.6.3.3.4. Intrathecal
16.6.3.3.5. Intraventricular
16.6.3.3.6. Others
16.6.3.4. Rest of Latin America Oncology Pharmaceuticals Market
Revenue (US$ Mn) and Forecasts, By Dosage (mg)
16.6.3.4.1. 50 to 100
16.6.3.4.2. 200
16.6.3.4.3. 500
16.6.3.4.4. Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Indication
16.7.3. By Application
16.7.4. By Route of Administration
16.7.5. By Dosage (mg)
17.
Competitive Benchmarking
17.1. Market Share Analysis, 2020
17.2. Global Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18.
Player Profiles
18.1. Abbott Laboratories.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Amgen Inc.
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Astellas Pharma Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Cipla Inc.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Dr. Reddy’s Laboratories Ltd
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. F. Hoffmann-La Roche Ltd
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. GlaxoSmithKline plc
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Johnson & Johnson Services, Inc
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Merck Sharp & Dohme Corp.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Novartis Pharmaceuticals Corporation
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Pfizer Inc.
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Sanofi
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Sun Pharmaceutical Industries Ltd.
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Takeda Pharmaceutical Company Limited
18.14.1. Company Details
18.14.2. Company Overview
18.14.3. Product Offerings
18.14.4. Key Developments
18.14.5. Financial Analysis
18.14.6. SWOT Analysis
18.14.7. Business Strategies
18.15. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
